GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Quick Ratio

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Quick Ratio : 0.04 (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Algernon Pharmaceuticals's quick ratio for the quarter that ended in Nov. 2023 was 0.04.

Algernon Pharmaceuticals has a quick ratio of 0.04. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Algernon Pharmaceuticals's Quick Ratio or its related term are showing as below:

AGNPF' s Quick Ratio Range Over the Past 10 Years
Min: 0.04   Med: 7.18   Max: 133
Current: 0.04

During the past 9 years, Algernon Pharmaceuticals's highest Quick Ratio was 133.00. The lowest was 0.04. And the median was 7.18.

AGNPF's Quick Ratio is ranked worse than
98.33% of 1553 companies
in the Biotechnology industry
Industry Median: 3.53 vs AGNPF: 0.04

Algernon Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Algernon Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Quick Ratio Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 0.76 12.74 4.80 1.12 0.12

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.20 0.24 0.12 0.04

Competitive Comparison of Algernon Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Algernon Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Quick Ratio falls into.



Algernon Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Algernon Pharmaceuticals's Quick Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Quick Ratio (A: Aug. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.252-0)/2.018
=0.12

Algernon Pharmaceuticals's Quick Ratio for the quarter that ended in Nov. 2023 is calculated as

Quick Ratio (Q: Nov. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.089-0)/2.144
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (OTCPK:AGNPF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Algernon Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

By sperokesalga sperokesalga 03-01-2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

By Stock market mentor Stock market mentor 01-11-2023